India-based Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Inc., USA has introduced its Fingolimod Capsules, 0.5 mg in the US market. The product is the generic version of Gilenya Capsules, 0.5 mg, a multiple sclerosis drug from Novartis Pharmaceuticals. Sanjeev Krishan — Glenmark North America President said: “We are very pleased to bring to […]
Strides Pharma Science said that its stepdown fully-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has secured approval from the US Food and Drug Administration (USFDA) for Cyclosporine Softgel Capsules USP (Modified), 25 mg, 50 mg, and 100 mg. The immunosuppressant medication product is bioequivalent and therapeutically equivalent to Neoral Capsules 25 mg, 50 mg, […]
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up to $1.5 billion. As per the terms of the deal, the Swiss pharma giant will pay $800 million upfront followed by up to $700 million in potential additional milestone payments. Through the deal, Novartis will gain access […]
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval for its pioneering gene therapy, Luxturna (voretigene neparvovec). Targeted at both children and adults, Luxturna addresses vision impairment caused by a rare, inherited retinal dystrophy associated with biallelic RPE65 mutations. This long-awaited approval now extends the gene […]